Immunophenotyping of leukemia.

[1]  M. Cooper,et al.  Pre-B-cell leukemia. A new phenotype of childhood lymphoblastic leukemia. , 1978, The New England journal of medicine.

[2]  J. Casper,et al.  Shifts in expression of cell membrane phenotypes in childhood lymphoid malignancies at relapse. , 1979, Blood.

[3]  T. Lister,et al.  Acute lymphoblastic leukaemia associated antigen. III ALterations in expression during treatment and in relapse. , 1980, Leukemia research.

[4]  G. Janossy,et al.  Immunological monitoring of residual disease in treated thymic acute lymphoblastic leukaemia. , 1981, Leukemia research.

[5]  B. Camitta,et al.  Bone marrow and extramedullary variations of cell membrane antigen expression in childhood lymphoid neoplasias at relapse. , 1982, Leukemia research.

[6]  G. Mufti,et al.  Common ALL with pre-B-cell features showing (8;14) and (14;18) chromosome translocations. , 1983, Blood.

[7]  C. Pui,et al.  Lineage switch in acute leukemia. , 1984, Blood.

[8]  R. Levy,et al.  Discordance between surface and cytoplasmic expression of the Leu-4 (T3) antigen in thymocytes and in blast cells from childhood T lymphoblastic malignancies. , 1985, The Journal of clinical investigation.

[9]  S. Stass,et al.  Acute mixed lineage leukemia: clinicopathologic correlations and prognostic significance , 1985 .

[10]  H. Drexler,et al.  A case of TdT-positive B-cell acute lymphoblastic leukemia. , 1986, American journal of clinical pathology.

[11]  S. Bigner,et al.  Acute lymphoblastic leukemia of Burkitt's type (L3 ALL) with 8;22 and 14;18 translocations and absent surface immunoglobulins. , 1986, American journal of clinical pathology.

[12]  W. Vainchenker,et al.  Monoclonal antibodies specific for human platelet membrane glycoproteins bind to monocytes by focal absorption of platelet membrane fragments: an ultrastructural immunogold study. , 1987, Leukemia.

[13]  D. Campana,et al.  The cytoplasmic expression of CD3 antigens in normal and malignant cells of the T lymphoid lineage. , 1987, Journal of immunology.

[14]  D. Campana,et al.  Multiple chromosome abnormalities in a drug resistant TdT positive B-cell leukemia. , 1987, Leukemia research.

[15]  E. Thiel,et al.  Analyses of phenotype and genotype in acute lymphoblastic leukemias at first presentation and in relapse. , 1987, Blood.

[16]  H. Drexler,et al.  Classification of acute myeloid leukemias--a comparison of FAB and immunophenotyping. , 1987, Leukemia.

[17]  S. Jhanwar,et al.  Multiparameter characterization of L3 leukemia cell populations. , 1987, Leukemia research.

[18]  H. Stein,et al.  Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells , 1987 .

[19]  D. Mason,et al.  Detection of cells of megakaryocyte lineage in haematological malignancies by immuno‐alkaline phosphatase labelling cell smears with a panel of monoclonal antibodies , 1987, British journal of haematology.

[20]  J. Dongen,et al.  Cytoplasmic expression of the CD3 antigen as a diagnostic marker for immature T-cell malignancies , 1988 .

[21]  D. Catovsky,et al.  T-cell chronic lymphocytic leukaemia: the spectrum of mature T-cell disorders. , 1988, Nouvelle revue francaise d'hematologie.

[22]  D. Boue,et al.  Expression and structure of CD22 in acute leukemia. , 1988, Blood.

[23]  J. Finlay,et al.  Acute B-lymphocytic leukemia with L1 morphology: a report of two pediatric cases. , 1988, Leukemia.

[24]  R. Gale,et al.  What is hybrid acute leukemia? , 1989, Leukemia research.

[25]  A. Cork,et al.  Molecular heterogeneity in acute leukemia lineage switch , 1989 .

[26]  D. Campana,et al.  The reliability of cytoplasmic CD3 and CD22 antigen expression in the immunodiagnosis of acute leukemia: a study of 500 cases. , 1989, Leukemia.

[27]  E. Thiel,et al.  Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. , 1989, Blood.

[28]  W. Vainchenker,et al.  Limits of phenotypic markers for the diagnosis of megakaryoblastic leukemia. , 1989, Blood cells.

[29]  F. Behm,et al.  Heterogeneity of presenting features and their relation to treatment outcome in 120 children with T-cell acute lymphoblastic leukemia. , 1990, Blood.

[30]  Jonathan J. Shuster,et al.  Prognostic factors in childhood T-cell acute lymphoblastic leukemia: a Pediatric Oncology Group study , 1990 .

[31]  F. Behm,et al.  Myeloid-associated antigen expression lacks prognostic value in childhood acute lymphoblastic leukemia treated with intensive multiagent chemotherapy , 1990 .

[32]  A. Look,et al.  Prognostic significance of CD34 expression in childhood B-precursor acute lymphocytic leukemia: a Pediatric Oncology Group study. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  D. Campana,et al.  The immunologic detection of minimal residual disease in acute leukemia. , 1990, Blood.

[34]  D. Campana,et al.  Phenotypic, genotypic, cytochemical, and ultrastructural characterization of acute undifferentiated leukemia. , 1990, Leukemia.

[35]  M. Koehler,et al.  Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. , 1991, Blood.

[36]  C. Bartram,et al.  Use of polymerase chain reactions to monitor minimal residual disease in acute lymphoblastic leukemia patients. , 1991, Blood.

[37]  L. Robison,et al.  Second neoplasms after acute lymphoblastic leukemia in childhood. , 1991, The New England journal of medicine.

[38]  F. Behm,et al.  Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. , 1991, The New England journal of medicine.

[39]  D. Catovsky,et al.  Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. , 1991, Blood.

[40]  J J Shuster,et al.  Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. , 1991, Blood.

[41]  H. Gralnick,et al.  Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML‐MO) , 1991, British journal of haematology.

[42]  J. V. van Dongen,et al.  The IgM-associated protein mb-1 as a marker of normal and neoplastic B cells. , 1991, Journal of immunology.

[43]  E. Thiel,et al.  Review of the incidence and clinical relevance of myeloid antigen-positive acute lymphoblastic leukemia. , 1991, Leukemia.

[44]  P. Pandolfi,et al.  Rearrangements of the RAR‐α gene in acute promyelocytic leukaemia: , 1991 .

[45]  D. Campana,et al.  Stages of T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. , 1991, Blood.

[46]  S. Raimondi,et al.  Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. , 1991, Blood.

[47]  A. Freedman,et al.  Immunologic markers in non-Hodgkin's lymphoma. , 1991, Hematology/oncology clinics of North America.

[48]  Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. , 1992 .

[49]  J. Drach,et al.  Flow cytometric determination of atypical antigen expression in acute leukemia for the study of minimal residual disease. , 1992, Cytometry.

[50]  F. Behm,et al.  Different Molecular Consequences of the 1;19 Chromosomal Translocation in Childhood B - Cell Precursor Acute Lymphoblastic Leukemia , 1992 .

[51]  F. Behm,et al.  Morphologic, immunologic and cytogenetic studies in children with acute lymphoblastic leukemia at diagnosis and relapse: a Pediatric Oncology Group study. , 1992, Leukemia.

[52]  F. Behm,et al.  Distinctive immunophenotypic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children. , 1992, Blood.

[53]  T. Barbui,et al.  Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukaemia , 1992, The Lancet.

[54]  I. Bernstein,et al.  Expression of lymphoid-associated cell surface antigens by childhood acute myeloid leukemia cells lacks prognostic significance. , 1992, Blood.

[55]  D. Catovsky,et al.  The role of an anti‐myeloperoxidase antibody in the diagnosis and classification of acute leukaemia: a comparison with light and electron microscopy cytochemistry , 1992, British journal of haematology.

[56]  E. Estey,et al.  Correlation of CD2 expression with PML gene breakpoints in patients with acute promyelocytic leukemia. , 1992, Blood.

[57]  J. V. van Dongen,et al.  Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. , 1992, Leukemia.

[58]  X. Thomas,et al.  Surface marker expression in acute myeloid leukaemia at first relapse , 1992, British journal of haematology.

[59]  E. Solary,et al.  Surface markers in adult acute myeloblastic leukemia: correlation of CD19+, CD34+ and CD14+/DR--phenotypes with shorter survival. Groupe d'Etude Immunologique des Leucémies (GEIL). , 1992, Leukemia.

[60]  F. Behm,et al.  Lack of CD45 antigen on blast cells in childhood acute lymphoblastic leukemia is associated with chromosomal hyperdiploidy and other favorable prognostic features , 1992 .

[61]  F. Behm,et al.  Transitional pre-B-cell acute lymphoblastic leukemia of childhood is associated with favorable prognostic clinical features and an excellent outcome: a Pediatric Oncology Group study. , 1993, Leukemia.

[62]  A. Hagemeijer,et al.  Acute myeloid leukemia M4 with bone marrow eosinophilia (M4Eo) and inv(16)(p13q22) exhibits a specific immunophenotype with CD2 expression. , 1993, Blood.

[63]  A. Órfão,et al.  Expression of NK and lymphoid-associated antigens in blast cells of acute myeloblastic leukemia. , 1993, Leukemia.

[64]  H. Asaoku,et al.  Phenotypic difference of normal plasma cells from mature myeloma cells , 1993 .

[65]  E. Thiel,et al.  Acute myeloid leukemias expressing lymphoid-associated antigens: diagnostic incidence and prognostic significance. , 1993, Leukemia.

[66]  F. Behm,et al.  Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia. , 1993, Blood.

[67]  J. Shuster,et al.  Predictability of the t(1;19)(q23;p13) from surface antigen phenotype: implications for screening cases of childhood acute lymphoblastic leukemia for molecular analysis: a Pediatric Oncology Group study. , 1993, Blood.

[68]  J. V. van Dongen,et al.  Detection of residual disease in AML patients by use of double immunological marker analysis for terminal deoxynucleotidyl transferase and myeloid markers. , 1993, Leukemia.

[69]  F. Behm,et al.  N-CAM (CD56) expression by CD34+ malignant myeloblasts has implications for minimal residual disease detection in acute myeloid leukemia. , 1993, Leukemia.

[70]  M. Dyer,et al.  mb-1: A New Marker for B-Lineage Lymphoblastic Leukemia , 1993 .

[71]  E. Thiel,et al.  Recent Advances in Cell Biology of Acute Leukemia , 1993, Recent Results in Cancer Research.

[72]  F. Behm,et al.  Clinical significance of CD34 expression in childhood acute lymphoblastic leukemia. , 1993, Blood.

[73]  J. Yunis,et al.  Acute myeloid leukemia M4 with inv(16) (p13q22) exhibits a specific immunophenotype with CD2 expression [letter] , 1993 .

[74]  C. Pui,et al.  Clinical significance of CD10 expression in childhood acute lymphoblastic leukemia. , 1993, Leukemia.

[75]  F. Behm,et al.  Normal and aberrant T-cell receptor protein expression in T-cell acute lymphoblastic leukemia. , 1993, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[76]  E. Estey,et al.  Expression of unusual immunophenotype combinations in acute myelogenous leukemia. , 1993, Blood.

[77]  J. Rowley,et al.  Persistence of the 8;21 translocation in patients with acute myeloid leukemia type M2 in long-term remission. , 1993, Blood.

[78]  O. Majdic,et al.  Flow cytometric analysis of cell-surface and intracellular antigens in leukemia diagnosis. , 1994, Cytometry.

[79]  D. Catovsky,et al.  The immunological profile of B-cell disorders and proposal of a scoring system for the diagnosis of CLL. , 1994, Leukemia.

[80]  J. V. van Dongen,et al.  Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. , 1994, Blood.

[81]  D. Catovsky,et al.  The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. , 1994, Leukemia & lymphoma.

[82]  J. Bennett,et al.  The immunophenotype of acute promyelocytic leukemia (APL): an ECOG study. , 1994, Leukemia.

[83]  F. Behm,et al.  Immunologic, cytogenetic, and clinical characterization of childhood acute lymphoblastic leukemia with the t(1;19) (q23; p13) or its derivative. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  D. Catovsky,et al.  The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. , 1994, Blood.

[85]  E. Estey,et al.  Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). , 1994, Leukemia.

[86]  J. V. van Dongen,et al.  Immunophenotypic changes between diagnosis and relapse in childhood acute lymphoblastic leukemia. , 1995, Leukemia.

[87]  D. Catovsky.  Chronic lymphoproliferative disorders. , 1995, Current opinion in oncology.

[88]  A. Órfão,et al.  Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. , 1995, Leukemia.

[89]  D. Campana,et al.  Toward a clinically useful classification of the acute leukemias. , 1995, Leukemia.

[90]  D. Campana,et al.  Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. , 1995, Blood.

[91]  F. Caligaris‐cappio.  B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. , 1996, Blood.

[92]  S. Zupo,et al.  CD38 expression distinguishes two groups of B-cell chronic lymphocytic leukemias with different responses to anti-IgM antibodies and propensity to apoptosis. , 1996, Blood.

[93]  G. Schmitz,et al.  Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Working Group on Flow Cytometry and Image Analysis. , 1996, Leukemia.

[94]  G. Janossy,et al.  Leukemia-associated changes identified by quantitative flow cytometry. IV. CD34 overexpression in acute myelogenous leukemia M2 with t(8;21). , 1996, Blood.

[95]  H. Sather,et al.  CD2 antigen expression on leukemic cells as a predictor of event-free survival after chemotherapy for T-lineage acute lymphoblastic leukemia: a Children's Cancer Group study , 1996 .

[96]  I. Bernstein,et al.  Prediction of relapse of pediatric acute myeloid leukemia by use of multidimensional flow cytometry. , 1996, Journal of the National Cancer Institute.

[97]  I. Bernstein,et al.  Human homologue of the rat chondroitin sulfate proteoglycan, NG2, detected by monoclonal antibody 7.1, identifies childhood acute lymphoblastic leukemias with t(4;11)(q21;q23) or t(11;19)(q23;p13) and MLL gene rearrangements. , 1996, Blood.

[98]  A. Órfão,et al.  Phenotypic changes in acute myeloid leukaemia: implications in the detection of minimal residual disease. , 1996, Journal of clinical pathology.

[99]  J. Downing,et al.  Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age. , 1996, Blood.

[100]  A. Morley,et al.  Relationship between minimal residual disease and outcome in adult acute lymphoblastic leukemia. , 1996, Blood.

[101]  Marcos González,et al.  Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients , 1997 .

[102]  R. Liang,et al.  Natural killer cell lymphoma/leukemia: pathology and treatment , 1997, Hematological oncology.

[103]  R. Gascoyne,et al.  U.S.-Canadian Consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: data analysis and interpretation. , 1997, Cytometry.

[104]  G. Morgan,et al.  Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage , 1997, British journal of haematology.

[105]  G. Papa,et al.  Minimally differentiated acute myeloid leukemia (AML-M0): comparison of 25 cases with other French-American-British subtypes. , 1997, Blood.

[106]  F. Behm,et al.  Monoclonal antibodies specific to the acute lymphoblastic leukemia t(1;19)-associated E2A/pbx1 chimeric protein: characterization and diagnostic utility. , 1997, Blood.

[107]  C. Bloomfield,et al.  Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21)(q22;q22). , 1997, Blood.

[108]  F. Sigaux,et al.  The majority of myeloid‐antigen‐positive (My+) childhood B‐cell precursor acute lymphoblastic leukaemias express TEL‐AML1 fusion transcripts , 1997, British journal of haematology.

[109]  M. Slovak,et al.  Presence of t(8;21)(q22;q22) in myeloperoxidase-positive, myeloid surface antigen-negative acute myeloid leukemia. , 1997, American journal of clinical pathology.

[110]  P. Martiat,et al.  A prospective study of minimal residual disease in childhood B‐lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse , 1997, British journal of haematology.

[111]  J. Wiley,et al.  The functional phenotype of the primitive plasma cell in patients with multiple myeloma correlates with the clinical state. , 1997, Leukemia & lymphoma.

[112]  J. Radich,et al.  Detection of bcr-abl transcripts in Philadelphia chromosome-positive acute lymphoblastic leukemia after marrow transplantation. , 1997, Blood.

[113]  H. Sather,et al.  Clinical features and treatment outcome of children with myeloid antigen positive acute lymphoblastic leukemia: a report from the Children's Cancer Group. , 1997, Blood.

[114]  M. Cleary,et al.  E2A-PBX1 chimeric transcript status at end of consolidation is not predictive of treatment outcome in childhood acute lymphoblastic leukemias with a t(1;19)(q23;p13): a Pediatric Oncology Group study. , 1998, Blood.

[115]  Elaine Coustan-Smith,et al.  Immunological detection of minimal residual disease in children with acute lymphoblastic leukaemia , 1998, The Lancet.

[116]  Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood , 1998 .

[117]  J. Bennett,et al.  Acute myeloid leukaemia expressing the leucocyte integrin CD11b — a new leukaemic syndrome with poor prognosis: result of an ECOG database analysis , 1998 .

[118]  B. Gruhn,et al.  Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome , 1998, Leukemia.

[119]  D. Catovsky,et al.  Detection of minimal residual disease in B‐lineage acute lymphoblastic leukaemia by quantitative flow cytometry , 1998, British journal of haematology.

[120]  Joseph A. DiGiuseppe,et al.  Clinical utility of flow cytometry in the chronic lymphoid leukemias. , 1998, Seminars in oncology.

[121]  Roberti,et al.  Expression and functional role of urokinase‐type plasminogen activator receptor in normal and acute leukaemic cells , 1998, British journal of haematology.

[122]  A Orfao,et al.  Prognostic value of immunophenotypic detection of minimal residual disease in acute lymphoblastic leukemia. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[123]  H. Cavé,et al.  Clinical Significance of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia , 1998 .

[124]  M. Keating.  Chronic lymphocytic leukemia. , 1999, Seminars in oncology.

[125]  C. Kittas,et al.  B-chronic lymphocytic leukemia, small lymphocytic lymphoma, and lymphoplasmacytic lymphoma, including Waldenström's macroglobulinemia: a clinical, morphologic, and biologic spectrum of similar disorders. , 1999, Seminars in hematology.

[126]  A. Órfão,et al.  Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. , 1999, Blood.

[127]  D. Campana,et al.  Detection of minimal residual disease in acute leukemia by flow cytometry. , 1999, Cytometry.

[128]  Steven L. Allen,et al.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. , 1999, Blood.

[129]  A. Órfão,et al.  High‐sensitive immunophenotyping and DNA ploidy studies for the investigation of minimal residual disease in multiple myeloma , 1999, British journal of haematology.

[130]  E. Weir,et al.  A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection , 1999, Leukemia.

[131]  E. Matutes,et al.  Quantitative analysis of CD79b, CD5 and CD19 in mature B-cell lymphoproliferative disorders. , 1999, Haematologica.

[132]  J. Hernández-Rivas,et al.  The flow cytometric pattern of CD34, CD15 and CD13 expression in acute myeloblastic leukemia is highly characteristic of the presence of PML-RARalpha gene rearrangements. , 1999, Haematologica.

[133]  A. G. Bosanquet,et al.  CD79a detected by ZL7.4 separates chronic lymphocytic leukemia from mantle cell lymphoma in the leukemic phase. , 1999, Cytometry.

[134]  W. Hiddemann,et al.  Leukaemia‐associated immunophenotypes (LAIP) are observed in 90% of adult and childhood acute lymphoblastic leukaemia: detection in remission marrow predicts outcome , 1999, British journal of haematology.